Therefore, selectively blocking TNFR1, thus favoring TNFR2, may represent another strategy to stimulate TNFR2+ Tregs in the treatment of autoimmune diseases and GVHD. The gene discussed is TNFRSF1B; the disease is graft versus host disease.